1243245-18-2
Chemical Structure
GNF-6231
- CAS No.: 1243245-18-2
- Formula:C24H25FN6O2
- Molecular Weight:448.49
IUPAC Name: N-(5-(4-acetylpiperazin-1-yl)pyridin-2-yl)-2-(2'-fluoro-3-methyl-[2,4'-bipyridin]-5-yl)acetamide
InChIKey: AXXNRMISICMFNS-UHFFFAOYSA-N
SMILES: O=C(NC1=NC=C(N2CCN(C(C)=O)CC2)C=C1)CC3=CN=C(C4=CC(F)=NC=C4)C(C)=C3
Biological Activity: GNF-6231 is a porcupine (IC50= 0.8 nM), Pron, and endoplasmic reticulum protein inhibitor with oral activity. GNF-6231 has anticancer activity. GNF-6231 can prevent the activation of the Wnt pathway by blocking the secretion of all Wnt ligands. GNF-6231 can be used in the study of myocardial infarction[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
GNF-6231 | 99.63% | GNF-6231 is a porcupine (IC50= 0.8 nM), Pron, and endoplasmic reticulum protein inhibitor with oral activity. GNF-6231 has anticancer activity. GNF-6231 can prevent the activation of the Wnt pathway by blocking the secretion of all Wnt ligands. GNF-6231 can be used in the study of myocardial infarction. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
GNF-6231 (Standard) | ≥98% | GNF-6231 (Standard) is the analytical standard of GNF-6231 (HY-100408). This product is intended for research and analytical applications. GNF-6231 is a porcupine (IC50= 0.8 nM), Pron, and endoplasmic reticulum protein inhibitor with oral activity. GNF-6231 has anticancer activity. GNF-6231 can prevent the activation of the Wnt pathway by blocking the secretion of all Wnt ligands. GNF-6231 can be used in the study of myocardial infarction. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. Bastakoty, Dikshya et al. Temporary, Systemic Inhibition of the WNT/β-Catenin Pathway promotes Regenerative Cardiac Repair following Myocardial Infarct. Cell, stem cells and regenerative medicine vol. 2,2 (2016): 10.16966/2472-6990.111. [Content Brief]
- [2]. Kang, Sheng. Low-density lipoprotein receptor-related protein 6-mediated signaling pathways and associated cardiovascular diseases: diagnostic and therapeutic opportunities. Human genetics vol. 139,4 (2020): 447-459. [Content Brief]
- [3]. Raeisi, Mortaza et al. Porcn as a novel therapeutic target in cancer therapy: A review. Cell biology international vol. 46,12 (2022): 1979-1991. [Content Brief]
- [4]. Cheng, Dai et al. Discovery of Pyridinyl Acetamide Derivatives as Potent, Selective, and Orally Bioavailable Porcupine Inhibitors. ACS medicinal chemistry letters vol. 7,7 676-80. 10 May. 2016, [Content Brief]
Keywords
